High-dose chemotherapy for relapsed testicular germ cell tumours

Einhorn, L. H. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 8, 1777–1781 (1990).

Article  CAS  Google Scholar 

Hanna, N. H. & Einhorn, L. H. Testicular cancer — discoveries and updates. N. Engl. J. Med. 371, 2005–2016 (2014).

Article  Google Scholar 

Chovanec, M., Hanna, N., Cary, K. C., Einhorn, L. & Albany, C. Management of stage I testicular germ cell tumours. Nat. Rev. Urol. 13, 663–673 (2016).

Article  CAS  Google Scholar 

Beyer, J. et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J. Clin. Oncol. 39, 1553–1562 (2021).

Article  CAS  Google Scholar 

Gillessen, S. et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J. Clin. Oncol. 39, 1563–1574 (2021).

Article  CAS  Google Scholar 

Motzer, R. J. et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 67, 1305–1310 (1991).

Article  CAS  Google Scholar 

Mardiak, J. et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma 52, 497–501 (2005).

CAS  Google Scholar 

Motzer, R. J. Paclitaxel (Taxol) combination therapy for resistant germ cell tumors. Semin. Oncol. 27, 33–35 (2000).

CAS  Google Scholar 

Adra, N. et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J. Clin. Oncol. 35, 1096–1102 (2017).

Article  Google Scholar 

Feldman, D. R. et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J. Clin. Oncol. 28, 1706–1713 (2010).

Article  CAS  Google Scholar 

Lorch, A. et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J. Clin. Oncol. 29, 2178–2184 (2011).

Article  Google Scholar 

Li, M. C., Whitmore, W. F. Jr., Golbey, R. & Grabstald, H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174, 1291–1299 (1960).

Article  CAS  Google Scholar 

Hanna, N. & Einhorn, L. H. Testicular cancer — discoveries and updates. N. Engl. J. Med. 371, 2342 (2014).

Article  Google Scholar 

Rosenberg, B., Vancamp, L. & Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698–699 (1965).

Article  CAS  Google Scholar 

Higby, D. J., Wallace, H. J. Jr, Albert, D. J. & Holland, J. F. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer 33, 1219–1215 (1974).

Article  CAS  Google Scholar 

Einhorn, L. H. & Donohue, J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87, 293–298 (1977).

Article  CAS  Google Scholar 

Einhorn, L. H. & Williams, S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer 46, 1339–1344 (1980).

Article  CAS  Google Scholar 

Einhorn, L. H., Williams, S. D., Troner, M., Birch, R. & Greco, F. A. The role of maintenance therapy in disseminated testicular cancer. N. Engl. J. Med. 305, 727–731 (1981).

Article  CAS  Google Scholar 

Stoter, G. et al. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol. 4, 1199–1206 (1986).

Article  CAS  Google Scholar 

Williams, S. D. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316, 1435–1440 (1987).

Article  CAS  Google Scholar 

Powis, G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug. Metab. Rev. 14, 1145–1163 (1983).

Article  CAS  Google Scholar 

Bleyer, W. A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41, 36–51 (1978).

Article  CAS  Google Scholar 

Creasey, W. A. et al. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res. 36, 216–221 (1976).

CAS  Google Scholar 

Hillcoat, B. L., McCulloch, P. B., Figueredo, A. T., Ehsan, M. H. & Rosenfeld, J. M. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br. J. Cancer 38, 719–724 (1978).

Article  CAS  Google Scholar 

Ozols, R. F. et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J. Clin. Oncol. 6, 1031–1040 (1988).

Article  CAS  Google Scholar 

Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490–2518 (2010).

Article  CAS  Google Scholar 

Blijham, G. et al. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur. J. Cancer 17, 433–441 (1981).

Article  CAS  Google Scholar 

Mulder, P. O. et al. Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur. J. Cancer Clin. Oncol. 24, 675–679 (1988).

Article  CAS  Google Scholar 

Nichols, C. R. et al. Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol. 7, 932–939 (1989).

Article  CAS  Google Scholar 

Broun, E. R. et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med. 117, 124–128 (1992).

Article  CAS  Google Scholar 

Einhorn, L. H. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Cancer Chemother. Pharmacol. 18, S45–S50 (1986).

Article  Google Scholar 

Harstrick, A. et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J. Clin. Oncol. 9, 1549–1555 (1991).

Article  CAS  Google Scholar 

Nichols, C. R. et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J. Clin. Oncol. 10, 558–563 (1992).

Article  CAS  Google Scholar 

Ayash, L. J. et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplant. 27, 939–947 (2001).

Article  CAS  Google Scholar 

Einhorn, L. H. et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N. Engl. J. Med. 357, 340–348 (2007).

Article  CAS  Google Scholar 

Motzer, R. J. et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer 69, 550–556 (1992).

Article  CAS  Google Scholar 

Pizzocaro, G. et al. Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann. Oncol. 3, 211–216 (1992).

Article  CAS  Google Scholar 

Vaena, D. A., Abonour, R. & Einhorn, L. H. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J. Clin. Oncol. 21, 4100–4104 (2003).

Article  CAS  Google Scholar 

Lorch, A. et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann. Oncol. 21, 820–825 (2010).

Article  CAS  Google Scholar 

Siegert, W. et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J. Clin. Oncol. 12, 1223–1231 (1994).

Article  CAS  Google Scholar 

Beyer, J. et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79, 161–168 (1997).

Article  CAS  Google Scholar 

Beyer, J., Stenning, S., Gerl, A., Fossa, S. & Siegert, W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol. 13, 599–605 (2002).

Article  CAS  Google Scholar 

Motzer, R. J. et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J. Clin. Oncol. 14, 1098–1105 (1996).

Article  CAS  Google Scholar 

Rick, O. et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol. 19, 81–88 (2001).

Article  CAS 

留言 (0)

沒有登入
gif